The global biopharmaceutical outsourcing market is expected to grow at a strong CAGR of 12.5% ​​during the forecast period 2022-2028. The pace of biopharmaceutical development is accelerating and more and more clinical trials are being conducted. Outsourcing partners with platform solutions and expertise, know-how and technology are sought after by many pharmaceutical companies to develop cost-effective methods. Growth in the biopharmaceutical outsourcing market is constrained by high capital, engineering, regulatory, and customer acquisition costs. Biopharmacy is very expensive compared to traditional small molecule drugs, but it is also very beneficial to patients and has been proven to guarantee higher profit margins for pharmaceutical companies.